Search

Displaying results 2171 - 2180 of 8412 in total
  1. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 Substrates
  2. Drug

    PF-04447943

    go.drugbank.com/drugs/DB11953
    Investigational

    PF-04447943 has been investigated for the treatment of Alzheimer's Disease.

    Synonyms: 4H-pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-6-((3S,4S)-4-methyl-1-(2-pyrimidinylmethyl)-3-pyrrolidinyl)-1-(tetrahydro-2H-pyran-4-yl)-, 6-((3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
  3. Drug

    PF-00446687

    go.drugbank.com/drugs/DB12517
    Investigational

    PF-00446687 has been investigated for the treatment of Erectile Dysfunction.

  4. Drug

    Chlorcyclizine

    go.drugbank.com/drugs/DB08936
    Approved

    Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic.

    Mixtures: biclora-D, biclora-DInternational brands: Di-Paralene
  5. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  6. Drug

    PD-169316

    go.drugbank.com/drugs/DB17040
    Experimental

    PD-169316 is a p38 MAP kinase inhibitor.[A253062]

  7. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]

  8. Drug

    Mevidalen

    go.drugbank.com/drugs/DB19034
    Investigational

    Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or

  9. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products. … It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285].

  10. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Nu-carvedilol, Ran-carvedilol